

2-Aminoethyl Diphenylborinate (2-APB) Analogues: Part 4 - Poly-Boron Compounds: Regulators of Ca²⁺ Release and Consequent Cellular Processes

Shoichiro Ozaki*

The Institute of Physical and Chemical Research, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan

Abstract

Inhibitory activities of 74 poly-boron compounds for SOCE and IICR were measured. Activities of poly-boron compounds were compared with 2APB, mono-boron and bis-boron compounds. The IC₅₀ of best poly-boron compound 1042 was 2 μM. This value was almost same as IC₅₀ 3 μM of 2-APB. Poly (aminoethoxyboryldiphenylether) 1042 is best candidate for regulation of Ca²⁺ release and consequent cellular processes in this paper.

Keywords: 2-APB; 2-APB analogue; Poly-boron compound; Regulator of Ca²⁺ release; Regulator of cellular processes

Introduction

Extracellular signal molecules attach to the plasmatic membrane where they are recognized by cell surface receptors. Upon binding of the ligand to the appropriate receptor, activation of G protein activates in turn phospholipase C. Active phospholipase C hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP₂) giving rise to two products: 1,2-diacylglycerol and inositol 1,4,5-triphosphate (IP₃). IP₃ stimulates the release of Ca²⁺ from the intracellular stores in the endoplasmic reticulum through IP₃ receptor while regulating a wide range of cellular processes [1-20].

In 1997, we identified 2-aminoethyl diphenylborinate (2-APB) as being an IP₃ receptor inhibitor and regulate IP₃-induced calcium release [21,22]. This discovery rose a substantial interest and had a great impact as it gained more than 600 citations and more than 1000 studies on 2-APB [23-37] have been published so far. This was supported by increasing sales of 2-APB by Sigma-Aldrich as membrane-permeable modulator of intracellular IP₃-induced cellular calcium release. In this study, we aimed to generate better modulator of calcium release than 2-APB.

We synthesized several 2-APB analogues and measured their inhibitory activities on Store-Operated Calcium Entry (SOCE) and IP₃ Induced Calcium Release (IICR). We found that bis boron compound DBP 161 and DBP 163 were 10 times more effective than 2-APB [38]. Previously, we studied bis- boron compounds in more detail [39,40]. We extended these studies and synthesized 493 2-APB analogues and measured their inhibitory activities on SOCE and IICR [38-44]. The numbers of compounds and data obtained are so many. We decided to report the results by dividing into three part.; Part 1 (mono-boron compounds), Part 2 (bis-boron compounds), and Part 3 (poly -boron compounds). We have reported about mono-boron compounds [45] and bis-boron compounds recently [46]. This time, we report about poly-boron compounds. Here we analyzed SOCE inhibitory activities and IICR inhibitory activities of our poly-boron compounds collection.

We believe that if we would regulate Ca²⁺ release and associated cellular processes by boron compounds with various Ca²⁺ release-related activities, we may therapeutically intervene in many diseases, such as heart diseases and Alzheimer`s disease.

Materials and Methods

2-APB analogues

2-APB was first synthesized by Ronderstvent et al. [47] in 1954 from triphenylboranes and ethanolamine. Later, hydroxy diphenyl borane and ethanolamine methods for 2-APB synthesis were reported by Weidman and Zimmermann [48], Letsinger and Skoog [49], Povlock and Lippincott [50].

We have synthesized 493 2-APB analogues [38-44] using methods described by us [38-44] and others [47-52]. The structures, names and synthetic methods of the 493 compounds are in example 1-493 of Ref. 44. We will show examples to prepare 7142, 8001, 1053 and 1060. Other compounds can be obtained by similar methods [44].

Preparation of poly (1,4-phenylenoxy-1,4-phenylenehydroxy-borane 7142: 4,4'-Dibromodiphenylether 328 mg was dissolved in ether(10ml),sec-butyl lithium 2 ml was added at -95°C and the mixture was warmed to -78°C 30 min later. Thereto was added triisopropoxyborane 188 mg and the mixture was stirred for 1 hr. The mixture was gradually warmed and stirred at room temperature for 15 hr. The mixture was acidified with 1N hydrochloric acid and the organic layer was washed with water, dried, concentrated, and subjected to silica gel column chromatography to give the title compound 112 mg.

Preparation of poly (aminoethoxyboryldiphenylether) 8001: 7142 (48.8 mg) was dissolved in ethanol 1.5 ml. Ethanolamine 15.7 mg was added and stirred overnight. N-hexane 10 ml was added and filtered to get 8001 11.7 mg as white solid.

Preparation of bis-(4,4'-(phenylglutamineboryl) phenyl) ether 1024: 4,4'-(hydroxyphenylboryl)diphenyl ether 1012 22 mg was

*Corresponding author: Shoichiro Ozaki, The Institute of Physical and Chemical Research, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan, Tel: 81-0467670991; Fax: 81-0467670991; E-mail: ozaki-0991@m.jcnnet.jp

Received September 05, 2014; Accepted October 07, 2014; Published October 14, 2014

Citation: Ozaki S (2014) 2-Aminoethyl Diphenylborinate (2-APB) Analogues: Part 4 - Poly-Boron Compounds: Regulators of Ca²⁺ Release and Consequent Cellular Processes. J Bioengineer & Biomedical Sci 4: 134. doi:10.4172/2155-9538.1000134

Copyright: © 2014 Ozaki S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

dissolved in ethanol 0.2 ml and water 2 ml Ethanolamine 19 mg was added. The reaction mixture was heated for 17 hrs at 80°C. Ether 10 ml was added to get 1024 17 mg as white precipitate.

Preparation of poly((4,4'-phenylene-hydroxyborane -4,4'-diphenylether)hydroxyborane) 1053: 1,4-Dibromobenzene 18 mg was dissolved in ether 10 ml, and sec-butyl lithium 1.05 ml was added at -96°C. stirred 1 hr (solution A) 4,4'-dibromodiphenylether 164 mg was dissolved in ether 6 ml, and the solution was cooled to at -78°C. Thereto was added 1N sec-butyl lithium 1 ml and the mixture was stirred for 30 min. Tris isopropoxyborane 230 mg was added and the mixture was stirred at -65°C (solution B).

Solution A and solution B was mixed and the solution was gradually warmed and stirred at room temperature for 15 hr. The mixture was acidified with 1N hydrochloric acid, and the organic layer was washed with water and dried and concentrated to give the title compound 178 mg.

Preparation of poly(phenyleneaminoethoxyborane diphenylether - aminoethoxyborane) 1060: Poly((4,4'-phenylene-hydroxyborane-4,4'-diphenylether hydroxyborane) 1053 36 mg was dissolved in ethanol 0.2 ml and ethanolamine 19 mg was added. The reaction mixture was stirred for 2 hr. Ether 10 ml was added to get 1060 36 mg as white precipitate.

Methods

We have assayed the inhibitory activity of the 2-APB analogues for SOCE and IICR using our improved assays described previously [45].

Results and Discussion

We measured inhibitory activities of poly-boron compounds for SOCE and IICR. The results are shown in Figure 1, shown as supplementary file.

From Figure 1, typical 18 poly boron compounds are selected as follow.

Comparison of 2APB, mono-boron compounds, bis-boron compounds and poly-boron compounds

- The IC₅₀ of best poly-boron compound 1042 at this paper is 2 μM.
- The IC₅₀ of 2-APB for SOCE inhibition is 3 μM. That is, the IC₅₀ of poly-boron compounds showed almost same activity as 2-APB.
- The IC₅₀ of best mono-boron compound 919 at first paper [45] is 0.2 μM. The IC₅₀ of best bis-boron compound 1024 reporting at previous paper [46] is 0.2 μM.

That is, the mono-boron compounds and bis-boron compounds showed almost 10 times strong activity than poly-boron compounds. Poly-boron compound does not fit well to IP₃ receptor, because of bulkiness of the molecule and does not inhibit IP₃-induced calcium release strongly.

These compounds can thus regulate the Ca²⁺ release and consequent cellular response.

Some of these compounds were shown to inhibit the calcium dependent enzyme transglutaminase [44]. Transglutaminase inhibitors block the abnormal cross-link of protein [43,44] and therefore they may slow down or even stop the progression of diseases caused by misfolded proteins, such as Huntington's disease.

The 2-APB analogues presented in this study could be proven to

be excellent lead compounds for many human diseases including heart disorders [53], Alzheimer's [54,55] and Huntington's disease [56,57].

We have shown widely different kinds of active compounds with IC₅₀ ranging 0.2 to 50 μM from mono-boron, bis-boron and poly-boron compounds. By choosing the compound we can control the release of Ca²⁺ and regulate many cellular processes such as secretion, cardiac contraction, fertilization, proliferation, synaptic plasticity, atrial arrhythmias [31], inhibition of calcium entry channel [25], excitation-contraction coupling in the heart [32], arrhythmogenic action of endothelin-1 on ventricular cardiac myocytes [34], dysregulation of neural calcium signaling in Alzheimer disease [55], Huntington aggregation [56,57] and protein cross-link by transglutaminase [43].

We believe that many investigators will find these reagents regulating Ca²⁺ release and related cellular processes very useful.

Summary

We have shown widely different kinds of active compounds with IC₅₀ ranging 0.2 to 50 μM. Mono-boron compounds (at Part 1 [45]) showed strongest and followed by bis-boron compounds (at Part 2 [46]) and poly-boron compounds (at Part 4 this paper). Among poly-boron compounds, poly (phenyleneaminoethoxyborane diphenylether-aminoethoxyborane) 1060, poly (aminoethoxyboryldiphenylether) 8001 and poly(4-4'-biphenylene N-methylaminoethoxyborane) 1030 are best 3 candidates for regulation of Ca²⁺ release and consequent cellular processes.

Acknowledgement

We would like to thank Dr. M. J. Berridge for valuable suggestions and advices.

References

1. Berridge MJ, Dawson RM, Downes CP, Heslop JP, Irvine RF (1983) Changes in the levels of inositol phosphates after agonist-dependent hydrolysis of membrane phosphoinositides. *Biochem J* 212: 473-482.
2. Berridge MJ (1983) Rapid accumulation of inositol trisphosphate reveals that agonists hydrolyse polyphosphoinositides instead of phosphatidylinositol. *Biochem J* 212: 849-858.
3. Streb H, Irvine RF, Berridge MJ, Schulz I (1983) Release of Ca²⁺ from a nonmitochondrial intracellular store in pancreatic acinar cells by inositol-1,4,5-trisphosphate. *Nature* 306: 67-69.
4. Berridge MJ, Heslop JP, Irvine RF, Brown KD (1984) Inositol trisphosphate formation and calcium mobilization in Swiss 3T3 cells in response to platelet-derived growth factor. *Biochem J* 222: 195-201.
5. Fein A, Payne R, Corson DW, Berridge MJ, Irvine RF (1984) Photoreceptor excitation and adaptation by inositol 1,4,5-trisphosphate. *Nature* 311: 157-160.
6. Brown JE, Rubin LJ, Ghalayini AJ, Tarver AP, Irvine RF, et al. (1984) myo-Inositol polyphosphate may be a messenger for visual excitation in *Limulus* photoreceptors. *Nature* 311: 160-163.
7. Burgess GM, Godfrey PP, McKinney JS, Berridge MJ, Irvine RF, et al. (1984) The second messenger linking receptor activation to internal Ca release in liver. *Nature* 309: 63-66.
8. Prentki M, Biden TJ, Janjic D, Irvine RF, Berridge MJ, et al. (1984) Rapid mobilization of Ca²⁺ from rat insulinoma microsomes by inositol-1,4,5-trisphosphate. *Nature* 309: 562-564.
9. Irvine RF, Brown KD, Berridge MJ (1984) Specificity of inositol trisphosphate-induced calcium release from permeabilized Swiss-mouse 3T3 cells. *Biochem J* 222: 269-272.
10. Irvine RF, Letcher AJ, Heslop JP, Berridge MJ (1986) The inositol tris/tetrakisphosphate pathway--demonstration of Ins(1,4,5)P₃ 3-kinase activity in animal tissues. *Nature* 320: 631-634.
11. Rapp RE, Berridge MJ (1981) The control of transepithelial potential oscillations in the salivary gland of *Calliphora erythrocephala*. *Exp Biol* 93: 119-132.

12. Missiaen L, Taylor CW, Berridge MJ (1991) Spontaneous calcium release from inositol trisphosphate-sensitive calcium stores. *Nature* 352: 241-244.
13. Berridge MJ, Irvine RF (1984) Inositol trisphosphate, a novel second messenger in cellular signal transduction. *Nature* 312: 315-321.
14. Berridge MJ (1987) Inositol trisphosphate and diacylglycerol: two interacting second messengers. *Annu Rev Biochem* 56: 159-193.
15. Berridge MJ, Irvine RF (1989) Inositol phosphates and cell signalling. *Nature* 341: 197-205.
16. Berridge MJ, Downes CP, Hanley MR (1989) Neural and developmental actions of lithium: a unifying hypothesis. *Cell* 59: 411-419.
17. Berridge MJ (1993) Inositol trisphosphate and calcium signalling. *Nature* 361: 315-325.
18. Bootman MD, Berridge MJ (1995) The elemental principles of calcium signaling. *Cell* 83: 675-678.
19. Berridge MJ (1993) Cell signalling. A tale of two messengers. *Nature* 365: 388-389.
20. Decrock E, De Bock M, Wang N, Gadicherla AK, Bol M, et al. (2013) IP₃, a small molecule with a powerful message. *Biochim Biophys Acta* 1833: 1772-1786.
21. Maruyama T, Kanaji T, Nakade S, Kanno T, Mikoshiba K (1997) 2APB, 2-aminoethoxydiphenyl borate, a membrane-penetrable modulator of Ins(1,4,5) P₃-induced Ca²⁺ release. *J Biochem* 122: 498-505.
22. Iwasaki H, Mori Y, Hara Y, Uchida K, Zhou H, et al. (2001) 2-Aminoethoxydiphenyl borate (2-APB) inhibits capacitative calcium entry independently of the function of inositol 1,4,5-trisphosphate receptors. *Receptors Channels* 7: 429-439.
23. Bilmen JG, Michelangeli F (2002) Inhibition of the type 1 inositol 1,4,5-trisphosphate receptor by 2-aminoethoxydiphenylborate. *Cell Signal* 14: 955-960.
24. Ma HT, Venkatachalam K, Parys JB, Gill DL (2002) Modification of store-operated channel coupling and inositol trisphosphate receptor function by 2-aminoethoxydiphenyl borate in DT40 lymphocytes. *J Biol Chem* 277: 6915-6922.
25. Dobrydyneva Y, Blackmore P (2001) 2-Aminoethoxydiphenyl borate directly inhibits store-operated calcium entry channels in human platelets. *Mol Pharmacol* 60: 541-552.
26. Bilmen JG, Wootton LL, Godfrey RE, Smart OS, Michelangeli F (2002) Inhibition of SERCA Ca²⁺ pumps by 2-aminoethoxydiphenyl borate (2-APB). 2-APB reduces both Ca²⁺ binding and phosphoryl transfer from ATP, by interfering with the pathway leading to the Ca²⁺-binding sites. *Eur J Biochem* 269: 3678-3687.
27. Missiaen L, Callewaert G, De Smedt H, Parys JB (2001) 2-Aminoethoxydiphenyl borate affects the inositol 1,4,5-trisphosphate receptor, the intracellular Ca²⁺ pump and the non-specific Ca²⁺ leak from the non-mitochondrial Ca²⁺ stores in permeabilized A7r5 cells. *Cell Calcium* 29: 111-116.
28. Peppiatt CM, Collins TJ, Mackenzie L (2003) 2-Aminoethoxydiphenyl borate (2-APB) antagonises inositol 1,4,5-trisphosphate-induced calcium release, inhibits calcium pumps and has a use-dependent and slowly reversible action on store-operated calcium entry channels. *Cell Calcium* 34: 97-108.
29. Luo D, Broad LM, Bird GS, Putney JW Jr (2001) Signaling pathways underlying muscarinic receptor-induced [Ca²⁺]_i oscillations in HEK293 cells. *J Biol Chem* 276: 5613-5621.
30. Bootman MD, Young KW, Young JM, Moreton RB, Berridge MJ (1996) Extracellular calcium concentration controls the frequency of intracellular calcium spiking independently of inositol 1,4,5-trisphosphate production in HeLa cells. *Biochem J* 314: 347-354.
31. Mackenzie L, Bootman MD, Berridge MJ, Lipp P (2001) Predetermined recruitment of calcium release sites underlies excitation-contraction coupling in rat atrial myocytes. *J Physiol* 530: 417-429.
32. Lipp P, Laine M, Tovey SC, Burrell KM, Berridge MJ, et al. (2000) Functional InsP₃ receptors that may modulate excitation-contraction coupling in the heart. *Curr Biol* 10: 939-942.
33. Mackenzie L, Bootman MD, Laine M, Berridge MJ, Thuring J, et al. (2002) The role of inositol 1,4,5-trisphosphate receptors in Ca(2+) signalling and the generation of arrhythmias in rat atrial myocytes. *Physiol* 541: 395-409.
34. Proven A, Roderick HL, Conway SJ, Berridge MJ, Horton JK, et al. (2006) Inositol 1,4,5-trisphosphate supports the arrhythmogenic action of endothelin-1 on ventricular cardiac myocytes. *J Cell Sci* 119: 3363-3375.
35. Berridge MJ, Bootman MD, Roderick HL (2003) Calcium signalling: dynamics, homeostasis and remodelling. *Nat Rev Mol Cell Biol* 4: 517-529.
36. Berridge MJ (2006) Remodelling Ca²⁺ signalling systems and cardiac hypertrophy. *Biochem Soc Trans* 34: 228-231.
37. Berridge MJ (2006) Calcium microdomains: organization and function. *Cell Calcium* 40: 405-412.
38. Zhou H, Iwasaki H, Nakamura T, Nakamura K, Maruyama T, et al. (2007) 2-Aminoethyl diphenylborinate analogues: selective inhibition for store-operated Ca²⁺ entry. *Biochem Biophys Res Commun* 352: 277-282.
39. Suzuki AZ, Ozaki S, Goto J, Mikoshiba K (2010) Synthesis of bisboron compounds and their strong inhibitory activity on store-operated calcium entry. *Bioorg Med Chem Lett* 20: 1395-1398.
40. Goto J, Suzuki AZ, Ozaki S, Matsumoto N, Nakamura T, et al. (2010) Two novel 2-aminoethyl diphenylborinate (2-APB) analogues differentially activate and inhibit store-operated Ca(2+) entry via STIM proteins. *Cell Calcium* 47: 1-10.
41. Mikoshiba K, Ozaki S, Suzuki A, Nakamura T (2007) Preparation of bisboron compounds controlling calcium concentration in cells.
42. <http://www.pherobase.com/database/journal/Jpn.%20Kokai%20Tokkyo%20Koho-journal.php>
43. Ozaki S, Ebisui E, Hamada K, Goto J, Suzuki AZ, et al. (2010) Potent transglutaminase inhibitors, aryl beta-aminoethyl ketones. *Bioorg Med Chem Lett* 20: 1141-1144.
44. http://worldwide.espacenet.com/publicationDetails/biblio?CC=WO&NR=2005058983&KC=&FT=E&locale=en_EP
45. Ozaki S, Suzuki AZ, Bauer PO, Ebisui E, Mikoshiba K (2013) 2-Aminoethyl diphenylborinate (2-APB) analogues: regulation of Ca²⁺ signalling. *Biochem Biophys Res Commun* 441: 286-290.
46. Ozaki S (2014) 2-Aminoethyl diphenylborinate (2-APB) analogues: Part 2.Regulators of Ca²⁺ release and consequent cellular processes. *Arches of Physiology* 1: 1-6.
47. Rondestvedt CS, Scriber RM, Wulfman CE (1955) Alcoholysis of triarylboranes. *J Org Chem* 20: 9-12.
48. Weidmann H, Zimmerman HK (1959) Borsäure-ester von N-substituierten Aminoalkoholen. *Justus Liebigs Ann Der Chemie* 619: 28-35.
49. Letsinger RL, Skoog IJ (1955) Organoboron Compounds. IV. Aminoethyl Diarylborinates. *J Am Chem Soc* 77: 2491-2494.
50. Povlock TP, Lippincott WT (1958) The Reaction of Trimethoxyboroxine with Aromatic Grignard Reagents. *J Am Chem Soc* 80: 5409-5411.
51. Brown HC, Colet TE (1983) Organoboranes. 31. A simple preparation of boronic esters from organolithium reagents and selected trialkoxyboranes. *Organometallics* 2: 1316-1319.
52. Mori Y, Kobayashi J, Manabe K, Kobayashi S (2002) Use of boron enolates in water. The first boron enolate-mediated diastereoselective aldol reactions using catalytic boron sources. *Tetrahedron* 58: 8263-8268.
53. Berridge MJ (1998) Neuronal calcium signaling. *Neuron* 21: 13-26.
54. Berridge MJ (2010) Calcium hypothesis of Alzheimer's disease. *Pflugers Arch* 459: 441-449.
55. Berridge MJ (2013) Dysregulation of neural calcium signaling in Alzheimer disease, bipolar disorder and schizophrenia. *Prion* 7: 2-13.
56. Bauer PO, Hudec R, Ozaki S, Okuno M, Ebisui E, et al. (2011) Genetic ablation and chemical inhibition of IP₃R1 reduce mutant huntingtin aggregation. *Biochem Biophys Res Commun* 416: 13-17.
57. Bauer PO, Hudec R, Goswami A, Kurosawa M, Matsumoto G, et al. (2012) ROCK-phosphorylated vimentin modifies mutant huntingtin aggregation via sequestration of IRBIT. *Mol Neurodegener* 7: 43.